In this podcast, expert clinicians will discuss the clinical data to support the use of oral antiviral treatments in mild-to-moderate COVID-19.
In this podcast, expert clinicians will discuss considerations and strategies for incorporating oral antiviral therapies into treatment paradigms for mild-to-moderate COVID-19.
In this podcast, expert clinicians will discuss current challenges regarding access to antiviral therapy for COVID-19.
In this podcast, expert clinicians will discuss the phases of COVID-19 infection, including the role of the adaptive immune response in progressive disease.
In this podcast, expert clinicians will discuss the management of influenza during the COVID-19 pandemic.
In this podcast, expert clinicians will discuss tools for patient assessment and diagnostic testing for influenza.
In this podcast, expert clinicians will discuss discussing methods to prevent the spread of influenza.
In this podcast, expert clinicians will discuss evidence-based management of influenza in adult patients at high-risk for complications.
In this podcast, expert clinicians will discuss best practices for the treatment of influenza in pediatric patients.
In this podcast, expert clinicians will discuss real-world evidence for pediatric influenza vaccines.
In this podcast, expert clinicians will discuss the comparative analysis of the currently available pediatric influenza vaccines.
In this podcast, expert clinicians will discuss the differences in influenza vaccine technologies.
In this podcast, expert clinicians will discuss the burden of influenza among the pediatric population and importance of influenza vaccination in children.
In this podcast, expert clinicians will discuss multidisciplinary care approaches to consider in tardive dyskinesia (TD). TD is a neurological disorder characterized by persistent involuntary movements that can be debilitating. It is commonly associated with exposure to dopamine receptor antagonists, including both typical and atypical antipsychotics. TD is associated with a high health care burden, but outcomes can be optimized through coordinated care efforts. Recently, the US Food and Drug Administration approved new treatments for patients with TD. Most providers are unfamiliar with these novel therapies and the discrepancies in their use. The other episodes in this series will cover the symptoms, pathology, causes, and burden of TD, as well as available therapies. Transcript: https://tinyurl.com/PrimaryCare3-4 For CME Credit, complete activity here: https://tinyurl.com/PrimaryCare3-4a
In this podcast, expert clinicians will discuss available therapies for tardive dyskinesia (TD). TD is a neurological disorder characterized by persistent involuntary movements that can be debilitating. It is commonly associated with exposure to dopamine receptor antagonists, including both typical and atypical antipsychotics. TD is associated with a high health care burden, but outcomes can be optimized through coordinated care efforts. Recently, the US Food and Drug Administration approved new treatments for patients with TD. Most providers are unfamiliar with these novel therapies and the discrepancies in their use. The other episodes in this series will cover the symptoms, pathology, causes, and burden of TD, as well as multidisciplinary care approaches to consider. Transcript: https://tinyurl.com/PrimaryCare3-3 For CME Credit, complete activity here: https://tinyurl.com/PrimaryCare3-3a
In this podcast, expert clinicians will discuss the burden of tardive dyskinesia (TD) on the patient and health care system. TD is a neurological disorder characterized by persistent involuntary movements that can be debilitating. It is commonly associated with exposure to dopamine receptor antagonists, including both typical and atypical antipsychotics. TD is associated with a high health care burden, but outcomes can be optimized through coordinated care efforts. Recently, the US Food and Drug Administration approved new treatments for patients with TD. Most providers are unfamiliar with these novel therapies and the discrepancies in their use. The other episodes in this series will cover the symptoms, pathology, and causes of TD, as well as available therapies, and multidisciplinary care approaches to consider. Transcript: https://tinyurl.com/PrimaryCare3-2 For CME Credit, complete activity here: https://tinyurl.com/PrimaryCare3-2a
In this podcast, expert clinicians will discuss the symptoms, pathology, and causes of tardive dyskinesia (TD). TD is a neurological disorder characterized by persistent involuntary movements that can be debilitating. It is commonly associated with exposure to dopamine receptor antagonists, including both typical and atypical antipsychotics. TD is associated with a high health care burden, but outcomes can be optimized through coordinated care efforts. Recently, the US Food and Drug Administration approved new treatments for patients with TD. Most providers are unfamiliar with these novel therapies and the discrepancies in their use. The other episodes in this series will cover the burden of TD, as well as available therapies, and multidisciplinary care approaches to consider. Transcript: https://tinyurl.com/PrimaryCare3-1 For CME Credit, complete activity here: https://tinyurl.com/PrimaryCare3-1a
While the impact of influenza varies, it places a substantial burden on the health of people in the United States each year. The Centers for Disease Control and Prevention estimates that influenza has resulted in between 9.3 million and 45 million illnesses, between 140,000 and 810,000 hospitalizations, as well as between 12,000 and 61,000 deaths annually since 2010. There is a need for better treatments for patients with influenza infection, preventative measures, and better mitigation for the impact associated with a pandemic. In this podcast, expert clinicians will discuss the latest updates on the treatment of influenza. Transcript: https://tinyurl.com/influenza2-5 For CME Credit, complete activity here: https://tinyurl.com/influenza2-5a
While the impact of influenza varies, it places a substantial burden on the health of people in the United States each year. The Centers for Disease Control and Prevention estimates that influenza has resulted in between 9.3 million and 45 million illnesses, between 140,000 and 810,000 hospitalizations, as well as between 12,000 and 61,000 deaths annually since 2010. There is a need for better treatments for patients with influenza infection, preventative measures, and better mitigation for the impact associated with a pandemic. In this podcast, expert clinicians will discuss the latest updates on the treatment of influenza. Transcript: https://tinyurl.com/influenza2-4 For CME credit, go here: https://tinyurl.com/influenza2-4a
While the impact of influenza varies, it places a substantial burden on the health of people in the United States each year. The Centers for Disease Control and Prevention estimates that influenza has resulted in between 9.3 million and 45 million illnesses, between 140,000 and 810,000 hospitalizations, as well as between 12,000 and 61,000 deaths annually since 2010. There is a need for better treatments for patients with influenza infection, preventative measures, and better mitigation for the impact associated with a pandemic. In this podcast, expert clinicians will discuss the latest updates on the treatment of influenza. Transcript: https://tinyurl.com/influenza2-3 For CME Credit, complete activity here: https://tinyurl.com/influenza2-3a